ganetespib (ADX-1612) / Aldeyra  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ganetespib (ADX-1612) / Aldeyra
Galaxy 2, NCT01798485 / 2012-004349-34: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Hourglass Jan 2016 - Dec 2016 : Final interim analysis of P3 GALAXY-2 trial for NSCLC
Hourglass Jul 2015 - Dec 2016 : Readout of results from GALAXY-2 trial
Not Appicable Jan 2016 - Dec 2016 : Final data from GALAXY-2 trial for NSCLC (Trial terminated)
Hourglass Feb 2015 - Mar 2016 : GALAXY-2 trial for advanced NSCLC
Terminated
3
696
US, Canada, Europe, RoW
Docetaxel, Taxotere, Docecad, Ganetespib, STA-9090
Synta Pharmaceuticals Corp.
Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
12/15
12/15
2013-002730-21: The AML18 Trial is an intensive chemotherapy trial for patients over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised 1600 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.

Ongoing
3
1000
Europe
AC220 (Quizartinib), Ganetespib, Mylotarg, Cladribine, STA9090, LITAK, LITAK
Cardiff University, Cancer Research UK
Acute Myeloid LeukaemiaHigh Risk Myelodysplastic Syndrome
 
 
2014-002195-90: The AML19 Trial is an intensive chemotherapy trial for patients between 18 and 60 with AML and High Risk Myelodysplastic disease.

Ongoing
3
2550
Europe
Gemtuzumab ozogamicin (mylotarg), Ganetespib, CPX351- Cytarabine, CPX351-Daunorubicin, STA9090,
Cardiff University, Cancer Research UK
Acute myeloid leukaemiaHigh Risk Myelodysplastic Syndrome
 
 
NCT01348126 / 2011-001084-42: Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Checkmark ESMO 2014 (GALAXY-1)
Sep 2014 - Sep 2014: ESMO 2014 (GALAXY-1)
Checkmark Final data from GALAXY-1 trial for advanced NSCLC
May 2014 - May 2014: Final data from GALAXY-1 trial for advanced NSCLC
Checkmark GALAXY-1 trial for NSCLC
More
Terminated
2b/3
385
US, Canada, Europe, RoW
Docetaxel, Combination of ganetespib and docetaxel
Synta Pharmaceuticals Corp.
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
04/14
10/15
2011-000749-19: AML LI1

Ongoing
2/3
800
Europe
AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Revlimid, STA9090, CHR-2797, KPT-330, EMEA/H/C/000717 -PSUV/0074, Revlimid, Revlimid
Cardiff University
Acute myeloid leukemia and high-risk myelodysplastic syndrome
 
 

Download Options